11/17/2025
As cardiovascular care continues to move toward value-based and ambulatory models, access to advanced diagnostics like Flyrcado™ is essential for driving clinical precision, improving operational throughput, and delivering greater value to patients.
We’re proud to share that following a successful pilot at Cardiovascular Medicine in Davenport, Iowa, GE HealthCare’s Flyrcado™ (flurpiridaz F 18)—a first-of-its-kind PET myocardial perfusion imaging (MPI) agent—is now expanding across 25 CVAUSA sites nationwide.
“Our mission is to deliver the highest quality cardiovascular care, and expanding the use of advanced cardiac PET imaging is a key part of that,”
— Tim Attebery , CEO, CVAUSA
Flyrcado integrates seamlessly into high-volume cardiac PET workflows, providing improved image quality and diagnostic confidence without disruption. With over 85,000 cardiac PET procedures performed annually across our network, this broader rollout reflects our ongoing commitment to supporting informed, efficient, and patient-centered care.
Read the full release from GE HealthCare:
https://www.gehealthcare.com/about/newsroom/press-releases/ge-healthcare-announces-flyrcado-milestone-strong-pilot-results-drive-broader-rollout-at-cvausa
